Patents by Inventor John Michael Beals

John Michael Beals has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins
    Patent number: 12059452
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: August 13, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
    Patent number: 11510967
    Abstract: The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 29, 2022
    Assignee: Eli Lilly and Company
    Inventors: John Michael Beals, Eric Dwayne Hawkins, Anthony Shane Ransdell, Shantanu Virendra Sule, Monica Rixman Swinney
  • FUSION PROTEINS
    Publication number: 20220211818
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: January 18, 2022
    Publication date: July 7, 2022
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins and methods of use
    Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • FUSION PROTEINS
    Publication number: 20200390865
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 17, 2020
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins
    Patent number: 10709766
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: July 14, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Blood glucose lowering compound
    Patent number: 10035839
    Abstract: The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: July 31, 2018
    Assignees: Eli Lilly and Company, Amunix Operating Inc.
    Inventors: David Bruce Baldwin, John Michael Beals, Andrew Ihor Korytko, Bryant Rhodius McLaughlin, Volker Schellenberger
  • FUSION PROTEINS
    Publication number: 20180177851
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 28, 2018
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Fusion proteins
    Patent number: 9855318
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: January 2, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • FUSION PROTEINS
    Publication number: 20160324932
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Application
    Filed: April 28, 2016
    Publication date: November 10, 2016
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Treatment for comorbid diabetes with chronic kidney disease
    Patent number: 9259479
    Abstract: The present invention relates to an improved method for treating diabetes wherein the improvement comprises administering a PEGylated insulin compound to a patient having moderate to severe chronic kidney disease using an effective amount of the compound.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: February 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Vikram Paritosh Sinha, Melvin Jay Prince, John Michael Beals
  • Pegylated Insulin Lispro Compounds
    Publication number: 20150297681
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: May 1, 2015
    Publication date: October 22, 2015
    Applicant: ELI LILLY AND COMPANY
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Ryan John Hansen, Shun Li, Lianshan Zhang, Brandon Doyle, Shahriar Shirani
  • PEGylated insulin lispro compounds
    Patent number: 9050371
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: June 9, 2015
    Assignee: Eli Lilly and Company
    Inventors: John Michael Beals, Gordon Butler Cutler, Jr., Ryan John Hansen, Shun Li, Lianshan Zhang
  • TREATMENT FOR COMORBID DIABETES WITH CHRONIC KIDNEY DISEASE
    Publication number: 20150111819
    Abstract: The present invention relates to an improved method for treating diabetes wherein the improvement comprises administering a PEGylated insulin compound to a patient having moderate to severe chronic kidney disease using an effective amount of the compound.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 23, 2015
    Inventors: Vikram Paritosh Sinha, Melvin Jay Prince, John Michael Beals
  • Pegylated Insulin Lispro Compounds
    Publication number: 20110105392
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: June 9, 2009
    Publication date: May 5, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Brandon Lee Doyle, Ryan John Hansen, Shun Li, Shahriar Shirani, Lianshan Zhang
  • PEGYLATED INSULIN LISPRO COMPOUNDS
    Publication number: 20090312236
    Abstract: The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 17, 2009
    Inventors: John Michael Beals, Gordon Butler Cutler, JR., Brandon Doyle, Ryan John Hansen, Shun Li, Sean Shirani, Lianshan Zhang
  • MUTEINS OF FIBROBLAST GROWTH FACTOR 21
    Publication number: 20090118190
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Application
    Filed: January 6, 2009
    Publication date: May 7, 2009
    Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
  • Muteins of fibroblast growth factor 21
    Patent number: 7491697
    Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: February 17, 2009
    Assignee: Eli Lilly and Company
    Inventors: John Michael Beals, Christopher Carl Frye, Wolfgang Glaesner, Shun Li, Radhakrishnan Rathnachalam, Jing Shang, Beth Ann Strifler, Radmila Micanovic
  • Heterologous G-Csf Fusion Proteins
    Publication number: 20080108560
    Abstract: The present invention encompasses heterologous fusion 5 proteins comprising a hyperglycsoylated G-CSF analog fused to proteins such as albumin and the Fc portion of animmunoglobulin which act to extend the in vivo half-life of the protein compared to native G-CSF. These fusion proteins are particularly suited for the treatment of conditions 10 treatable by stimulation of circulating neutrophils, such as after chemotherapy regimens or in chronic congenital neutropenia.
    Type: Application
    Filed: February 21, 2003
    Publication date: May 8, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: John Michael Beals, Uma Kuchibhotla
  • Hyperglycosylated polypeptides
    Publication number: 20040254351
    Abstract: The present invention addresses the need for better pharmaceutical agents for treating patients that have reduced circulating levels of neutrophilic granulocytes, such as after chemotherpay regimens or in chronic congenital neutropneia by providing novel biological active glycosylated G-CSF analogs.
    Type: Application
    Filed: February 19, 2003
    Publication date: December 16, 2004
    Inventors: John Michael Beals, Joe Christopher Berry, Marcia Kay Jones, Uma Kuchibhotla, Radhakrishnan Rathnachalam